Introduction {#S1}
============

Obesity is now considered a worldwide epidemic, with up to 35% of adults being considered overweight or obese. Women are more likely to develop such a phenotype ([@B1]), with female rates of obesity in the United States rising from 31.5% of women aged 60 or older in 2003--2004 to 38.1% in 2011--2012 ([@B2]). Obesity is highly correlated with inflammation in many tissues, including the central nervous system (CNS) ([@B3]). Obesity and nutrient overload can trigger proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1β, to build up in a number of affected tissues. Cells, including adipocytes and brain cells, respond to this metabolic stimulus through activation of different signaling pathways, including c-jun N-terminal kinase (JNK), inhibitor of nuclear factor kappa-B kinase (IKK), and the nuclear factor kappa-B (NF-κB) itself ([@B3]).

Diet plays a central role in obesity development, and a consensus on its exact influence is far from being defined. One way of seeing the effects of diet-related factors on obesity is evaluating leptin levels in the blood. Leptin resistance is a very common characteristic of obesity ([@B4]), and its serum levels are higher in obese humans when compared to healthy subjects ([@B5]). Regarding dietary intake, different factors affect leptin concentration and sensitivity differently, although several contradictory results can be found in the literature.

Regarding carbohydrate consumption, data are somewhat conflicting. While high glycemic index carbohydrate consumption or drastic high-carbohydrate diet (80% carbohydrate) may lead to leptin resistance ([@B6], [@B7]), different high-carbohydrate diets have no or the opposite effects on leptin sensitivity and blood concentrations ([@B8], [@B9]). On the other hand, fat intake has consistently been proven to be associated with a leptin resistance state ([@B10], [@B11]). There is, however, a divergence regarding the type of fat \[saturated, mono, or polyunsaturated fatty acids (PUFA)\] that is important for the effects on leptin levels ([@B12], [@B13]).

Accumulating data clearly show that a high-fat diet (HFD) negatively impacts on health, including increasing the incidence of cardiovascular diseases, diabetes, and overall mortality ([@B14]--[@B16]). HFD-exposed animals and humans also have an increased susceptibility to the development of a range of psychiatric disorders, which significantly correlates with body mass index (BMI) and obesity ([@B17]). Although BMI is widely used as an easy assessment of overall adiposity, studies show that abdominal fat deposition and visceral adiposity correlate more highly with metabolic ([@B18]) and psychiatric disorders ([@B19]). In that sense, another type of assessment, such as waist circumference and/or waist-to-hip ratio, is being used as a more relatable measurement that associates body fat and health disorders ([@B18]). Such correlation is greater in women than in men, which may indicate a difference between male and female responses to nutritional status in relation to mental health ([@B20], [@B21]).

On the other hand, dietary energy restriction (DER), achieved through a variety of protocols in which food intake is chronically or intermittently limited, can induce many beneficial outcomes, including *via* anti-inflammatory and antioxidant effects, that potentially increase lifespan \[reviewed in Ref. ([@B22])\]. A wide body of data show food availability to affect both the activation and the rhythmicity of the hypothalamic--pituitary--adrenocortical (HPA) axis ([@B23], [@B24]). Furthermore, glucocorticoids, a group of steroid hormones, can modulate a plethora of processes in the organism, including immune function and energy metabolism ([@B25]--[@B27]). Therefore, the involvement of the HPA axis, especially of the glucocorticoid, rodent corticosterone (human cortisol), in the beneficial effects of DER has been extensively studied. Not only may DER modulate the HPA axis but it may also influence the hypothalamic--pituitary--gonadal (HPG) axis ([@B28]--[@B32]), thereby potentially interfering with the levels of sex hormones, such as androgens and estrogens.

The levels of both glucocorticoids and sex hormones seem to be strongly associated with inflammatory processes ([@B26], [@B33]--[@B37]). Therefore, this review focuses on assessing the role of these steroid hormones in neuroinflammation and the modulation exerted by dietary interventions such as HFD and DER on this process.

Neuroinflammation and Steroidal Hormones {#S2}
========================================

Glucocorticoids {#S2-1}
---------------

Many studies have shown that glucocorticoids exert anti-inflammatory effects in the organism ([@B38]). Glucocorticoids secreted by the adrenal glands after a physiological or psychogenic stressful stimulus promote anti-inflammatory and immunosuppressant actions through several genomic and non-genomic mechanisms, including the increase of anti-inflammatory gene expression (e.g., inhibitor of NF-κB, IκB-α, and IL-1 receptor antagonist) and the inhibition of NF-κB and of proinflammatory cytokines (e.g., TNF-α and IL-1β) ([@B37], [@B39]--[@B41]). These mitigating effects on inflammation are frequently exploited in clinical settings to treat a plethora of inflammatory and immune conditions ([@B42], [@B43]).

The synthesis of glucocorticoids and proinflammatory cytokines are interconnected *via* autoregulatory feedback loops, with corticosterone inhibiting the synthesis of proinflammatory cytokines and these cytokines stimulating the release of glucocorticoids through the upregulation of adrenocorticotropic hormone release from the pituitary gland ([@B38], [@B44]). Glucocorticoids levels are elevated after an inflammatory stimulus, including when induced by lipopolysaccharide (LPS) ([@B45]). Interestingly, disrupting the glucocorticoid signaling, by adrenalectomy or using glucocorticoid receptor (GR) antagonists, results in a much higher sensitivity of mice to the lethal effects of LPS ([@B33], [@B46]--[@B51]). As such, glucocorticoids are important for the resolution of inflammatory processes.

However, unlike the acute anti-inflammatory properties of, and protection afforded by, glucocorticoids, chronically elevated glucocorticoid levels are harmful, including in the CNS ([@B52]). Glucocorticoids can actually potentiate, rather than blunt, neuroinflammation ([@B52]--[@B56]). Over evolution, it is clear that stressful events may be accompanied by an immunological challenge, such as from tissue damage, with glucocorticoid-induced immune suppression, in such circumstances, being maladaptive ([@B35]).

Munhoz et al. ([@B53]) showed that elevated acute corticosterone levels are proinflammatory in the CNS, enhancing LPS-induced NF-κB activation and proinflammatory gene expression, which is prevented by GR antagonist treatment. In another study, high corticosterone levels induced by chronic stress increase the TNF-α release and microglia activation induced by intracortical LPS injection, in a GR-dependent manner ([@B52]). Importantly, in this study, this reactivation-enhancing effect of glucocorticoids occurred even when the chronic stress occurred after the inflammatory stimulus. Furthermore, various studies have demonstrated that glucocorticoids increase the vulnerability of neurons to numerous insults, such as excitotoxins and global ischemia, rising neuronal death and worsening neurological outcomes ([@B54]--[@B56]).

It is important to note that glucocorticoids can have differential impacts on brain immunity in different brain regions. For instance, the glucocorticoid-mediated potentiation of the inflammatory markers induced by LPS occurs in the frontal cortex and hippocampus but with the opposite effect being evident in the hypothalamus ([@B57]). Thus, glucocorticoids increase or decrease CNS inflammation depending on the dose, timing, duration of glucocorticoid exposure, and the type of glucocorticoid compound ([@B35]). The precise mechanism that contributes to these paradoxical responses, although of the utmost importance, is still unknown. What is currently known is that whether glucocorticoids exert anti- or proinflammatory effects is context-dependent, with variable response dependent upon concentration, time of exposure, the compound type, and the nature of the stimulus \[reviewed in Ref. ([@B35])\]. The glucocorticoid-mediated effects on inflammation under physiological and chronic stress are summarized in Figure [1](#F1){ref-type="fig"}.

![**Dual effects of stressful stimuli on glucocorticoid-mediated regulation of inflammation**. Glucocorticoids released after a mild stressor results in anti-inflammatory actions, reducing the proinflammatory cytokines production and increasing the expression of anti-inflammatory proteins, such as IL-1ra and IκB-α. On the other hand, pathological stressful stimuli lead to chronically elevated glucocorticoids promoting proinflammatory actions, including microglia activation and the consequent upregulation of the NF-κB proinflammatory cascade.](fendo-07-00009-g001){#F1}

Sex Hormones {#S2-2}
------------

The association of sex hormones and inflammation markers has been widely discussed in the literature. For instance, levels of testosterone and sex hormone-binding globulin (SHBG) were inversely correlated to markers of metabolic syndrome ([@B58]) and inflammation \[e.g., C-reactive protein ([@B59]), γ-glutamyl transferase ([@B60]), and white blood cell and granulocyte count ([@B36])\]. Interestingly, male-derived cortical astrocytes show increased IL-6, TNF-α, and IL-1β mRNA levels in comparison to female-derived cells ([@B61]), indicating the importance of androgens as a modulator of central inflammation.

This correlation has also been supported by pharmacological approaches. Jayaraman et al. ([@B62]) observed that treatment with testosterone *in vitro* suppressed the increase in TNF-α expression in glial cultures from the cortices of animals submitted to a HFD. In addition, they observed a similar effect *in vivo* in gonadectomized mice, with a testosterone-mediated rescue of TNF-α and IL-1β mRNA levels in the cortex. Similarly, Khosla et al. ([@B63]) found an increase in serum TNF-α levels induced by acute, chemically induced hypogonadism in men. This effect was partially rescued by treatment with estrogen or testosterone, with a complete rescue being achieved by a combined therapy of both hormones ([@B63]). Accordingly, orchidectomized animals challenged with LPS show increased sickness behavior and increased levels of circulating IL-6 ([@B64]). This augmented reaction to LPS might be mediated by increased toll-like receptor (TLR)-4 signaling, as treatment with testosterone *in vitro* and *in vivo* decreases TLR-4 expression and sensitivity in macrophages ([@B64]). Testosterone also has a similar protective effect, in comparison with estradiol, in primary cultured neurons, where it prevents serum deprivation-induced apoptosis in an aromatase-independent manner, eliminating a possible indirect effect mediated by its conversion into estrogen ([@B65]).

In addition, testosterone is a potential neuroprotective factor against the inflammation associated with neurodegenerative disorders, such as Alzheimer's disease ([@B66]) and multiple sclerosis ([@B67]). However, this literature is confounded by mixed results, with studies showing either no ([@B60]) or a positive correlation of testosterone levels and inflammation markers ([@B68]). As well as testosterone, estrogens have also been depicted as neuroprotective and/or anti-inflammatory agents. In microglia, estradiol has a very prominent inhibitory effect. Six hours after a subcutaneous injection of estradiol in ovariectomized (OVX) rats, LPS-induced macrophage activation is reduced by 60--90% in the cerebral cortex and hippocampus, as measured by reduced expression of ED-1/CD68. Similarly, in a mouse model of Alzheimer's disease with plaque deposition, activated microglia surrounding amyloid plaques are greatly increased in OVX mice, which is reversed by an estradiol replacement therapy, although no effects over Aβ deposit levels were observed ([@B69]). Accordingly, an *in vitro* study showed similar estrogen effects, impairing microglial activation. The estrogens, estriol, and estradiol, as well as progesterone, suppress LPS-induced increase in inducible nitric oxide synthase (iNOS) expression and nitrite production in N9 microglial cells and in rat primary cultured microglia ([@B70], [@B71]). Estradiol was able to suppress nitric oxide (NO) and TNF-α increase, as well as cell death, in rat primary cultured glial cells challenged with LPS ([@B72]). Additionally, by stimulating BV-2 murine microglial cells with LPS, Baker et al. ([@B73]) showed estrogen pretreatment to decrease NO production, as well as iNOS and cyclooxygenase (COX)-2 expression, through interaction with the estrogen receptor (ER)-β ([@B73]). Albeit acute microglial activation could be essential to beneficial inflammatory processes, supporting the tissue in coping with stressors ([@B74]), the maintenance of a chronic inflammatory status is associated with the development of many pathologies, including neurodegenerative disorders such as Alzheimer's disease. These studies point out to the importance of estrogens as regulators of microglial activity, thus highlighting the potential of this mechanism as a way to modulate dysregulated inflammation.

Estradiol also has anti-inflammatory effects in astrocytes. Treatment with either estradiol or ER modulators inhibits astrocyte proliferation to a plethora of insults, such as stab wound injury ([@B75], [@B76]), kainic acid ablation ([@B77]), and in a MPTP model of Parkinson's disease ([@B78]). Additionally, estradiol also inhibits amyloid β (Aβ)-induced elevation in IL-1β and TNF-α levels, as well as COX-2 and iNOS expression, in primary cultured astrocytes ([@B79]). Estradiol treatment also attenuates the increased hippocampal expression of IL-1β and TNF-α, as well as astrocyte activation, in OVX rats, which is mediated *via* decreased NF-κB signaling ([@B80]). Moreover, a reduction in proinflammatory cytokine and chemokine mRNA content is observed in cultured astrocytes that have been prior-treated with estradiol and ER modulators before LPS stimulation ([@B81]).

Indeed, ER modulators seem to have anti-inflammatory effects, as proven in several *in vivo* and *in vitro* experimental models. Such data indicate that ER-α deletion, specifically in astrocytes (but not neurons), lowers the beneficial effects of an ER-α ligand treatment, in an experimental autoimmune encephalomyelitis (EAE) animal model, as seen by clinical function, central inflammation, and axonal loss on female mice ([@B82]). Additionally, astroglial cell death and mitochondrial function are rescued by an estradiol pretreatment in an *in vitro* oxygen/glucose deprivation model ([@B83]).

Likewise, *in vitro* astrocyte cultures have a diminished inflammatory response following ER manipulations, as seen by an ER-β-dependent reduction in NF-κB signaling ([@B84]), reduction in COX and iNOS expression ([@B79]), and overall reduction in proinflammatory cytokine release ([@B84]). In addition, estrogen has a positive effect on astrocytic glutamate re-uptake, by increasing glutamate transporters GLT-1 and GLAST ([@B85]), contributing to the functioning of glutamatergic synapses, as well as affording neuroprotection against the excitotoxic effects of raised levels of extracellular glutamate.

Many other *in vivo* models of inflammation also indicate estrogen to be neuroprotective. Estradiol reduces brain levels of TNF-α, IL-1β, and IL-6 in male rats in model of severe peripheral burning injury ([@B34]). Additionally, low doses of progesterone or high doses of estrogen attenuate the raised levels of IL-1β that are evident 24 h after a traumatic brain injury in female rats, although the sex hormones increased the cytokine levels in the early inflammatory phase ([@B86]). Interestingly, Zhang et al. ([@B87]) suggested that not only circulating but also brain-derived estrogen might act as anti-inflammatory modulator. They showed, in a model of global cerebral ischemia in female rats, that hippocampal astrocyte activation was associated with an increase in aromatase expression, with consequent elevations of estradiol levels in the CA1 region, while suppression of its expression through antisense oligonucleotides enhanced cell death as well as astrocyte and microglial activation ([@B87]).

Nonetheless, not all studies indicate beneficial effects of estrogens. Chronic estrogen treatment of OVX rats impairs their performance in a water maze test in a way that is similar to that of LPS. When both estrogen treatment and LPS were combined, performance was further decreased ([@B88]). Interestingly, although exerting an anti-inflammatory effect in young females, estradiol increases brain IL-1β levels in reproductively senescent rats ([@B89]), thus highlighting that aging might impair the protective response to estrogens. Accordingly, in a model of systemic lupus erythematosus in female mice, genetic deficiency of ER-α decreased Iba1^+^-activated microglia and rescued the cognitive deficit as assessed by the radial arm water maze test ([@B90]).

Overall, most studies suggest a protective effect of both testosterone and estrogens, although many factors may act to complicate such general conclusions, on occasion inverting these beneficial effects, which highlights the importance of further assessing the biological underpinnings that drive such complications. It is possible that the further assessment of testosterone/estrogen ratio -- instead of single hormone level analyses -- could help to further elucidate the reason for such paradoxical results, since it seems to have a greater physiological relevance ([@B30]). In addition, the complex effects of estrogens in inflammation might also be dependent on distinct activation of specific ER subtypes, ER-α and ER-β ([@B84], [@B91], [@B92]), and may also vary between different models.

Involvement of Steroid Hormones in Dietary Interventions {#S3}
========================================================

HFD and Glucocorticoids {#S3-1}
-----------------------

Behavioral impacts of chronic exposure to a HFD can last for months, and their progression develops differently depending on which stage of the lifespan HFD exposure occurs. For example, rats chronically exposed to a lipid overload in their pre- and postnatal period exhibit anxiety-like behavior when adults, as measured by open field and elevated plus maze tasks ([@B93], [@B94]). HFD consumption during pregnancy impairs maternal behavior in mice, increasing circulating levels of corticosterone. Although the fetus is usually protected against maternal glucocorticoids due to placenta expression of 11beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2), mice fed with a HFD have a lower expression of placental 11β-HSD2, rendering the fetus vulnerable to the effects of maternal circulating levels of glucocorticoids ([@B95]). Alterations in the gene expression of GRs in the amygdala as well as pro- and anti-inflammatory gene expression profiles in the amygdala and hippocampus of the offspring as adults could explain the increased anxiety-like behavior of animals exposed to HFD in pre- and perinatal periods of their early development ([@B94], [@B96]).

High-fat diet consumption by adult rats also alters their HPA axis response to stress, resulting in elevated glucocorticoid levels ([@B97]). Such altered response may be due to an increased noradrenergic input in the paraventricular nucleus (PVN) of the hypothalamus, an area responsible for controlling corticotrophin-releasing hormone (CRH) delivery to the pituitary. Indeed, HFD induces tyrosine hydroxylase expression in the PVN area and increases CRH levels in the median eminence, part of the hypophyseal portal system ([@B98]). Besides HPA axis regulation, HFD in adults has a clear impact on systemic and central inflammation, dysregulating inflammatory gene expression, which, among other disorders, plays a central role in the development of insulin resistance ([@B99], [@B100]).

Disruption of some components of corticosteroid signaling has also been reported in several rat brain regions following chronic HFD consumption. Regulation of mineralocorticoid receptors and GRs, respectively, seems to be region-specific, increasing in some brain areas and diminishing in others. After chronic exposure to HFD, hippocampi of female rats exhibit a lower expression of both corticosteroid receptors ([@B101]), while an increase in amygdala levels of MR and GR was observed ([@B94]). However, both of these alterations can have similar stress-regulatory effects, with amygdala GR activation enhancing the stress response, while a loss of the HPA axis suppressive effects of the hippocampal GR by HFD, leading to a loss of its inhibition of the stress response ([@B102]). As well as such hippocampal changes arising from chronic stress, they are also evident in wider neurodegenerative-associated processes, including aging ([@B103], [@B104]). In all these cases, reduced expression of hippocampal corticosteroid receptors is associated with an exaggerated response to stress, confirming the inhibitory effect of hippocampal projections on the HPA axis.

It is well known that NF-κB activity is affected by GR expression and signaling ([@B35]). Corticosterone, through GR activation, can induce apoptosis in lymphocytes ([@B105]), which explains the first observed data linking stress to immunosuppressant effects. Chronic supraphysiological levels of glucocorticoids are able to hinder immunity responses, reducing leukocyte count and impairing expression of several proinflammatory cytokines ([@B106]). Acting as an immunosuppressant, glucocorticoids have direct antagonizing effects upon NF-κB signaling, enhancing the expression of IκB and promoting the interaction between the GR and NF-κB in the nucleus, which, among many other effects, can decrease immune activation ([@B106]). On the other hand, increased immune response is also reported in initial phases of a stressful stimulus, an effect that is dependent upon basal levels of corticosterone ([@B107]). Given such a collection of data, it is not surprising that HFD can alter NF-κB activity and the expression of different inflammatory cytokines. In mouse peripheral tissues, the expression of NF-κB is increased in response to a chronic HFD. Enhanced NF-κB expression and activity was also reported in the amygdala of rats exposed to a HFD in their perinatal period ([@B94]), while diminished NF-κB expression is found in their hippocampus ([@B101]). Corroborating the central protective role of NF-κB, especially in the hippocampus, recent data show that a HFD can impair hippocampal neurogenesis, while elevating plasma corticosterone levels ([@B108]). Several other studies indicate different deleterious effects caused by a HFD upon hippocampal neuron functioning, including diminished BDNF production, impaired neuronal plasticity ([@B109], [@B110]), and working memory deficits ([@B111]). Interestingly, impaired hippocampal neurogenesis in HFD rodents does not correlate with fat accumulation but rather to serum corticosterone levels ([@B108]). In fact, high serum corticosterone levels affect proliferation, differentiation, and apoptosis in the dentate gyrus of rodents in different experimental settings ([@B112], [@B113]), indicating the significant role that alterations in the HPA axis play in HFD models.

The correlation between obesity and cognitive impairment has been extensively described in the past decade and several potential mechanisms were proposed trying to explain this link. Of these hypotheses, a few stand out. Impaired insulin and leptin signaling ([@B114], [@B115]) in the hippocampus and other memory-related brain regions is emerging as an interesting theory that forces us to further investigate the role of these two hormones in the physiology of the brain and specifically their purpose regarding synaptic function. However, considering the inflammatory pattern associated with obesity, it is not surprising that a large body of evidence supports the idea of a neuroinflammatory trigger to the cognitive deterioration associated with a HFD and obesity.

In this context, local proinflammatory cytokine production has been reported to occur in some brain regions after different HFD protocols ([@B116]--[@B118]). In all these cases, anti-inflammatory and/or antioxidant treatment (both pharmacological and non-pharmacological interventions) were able to revert HFD-induced cognitive impairment. This cognitive improvement seems to be accompanied not only by a reduction in inflammatory and oxidative stress markers but also with a reduced neuronal insulin resistance, driving a strong correlation between these factors.

Reinforcing the important role of neuroinflammation, several studies have also described an increase in blood--brain barrier (BBB) permeability caused by a HFD, in turn leaving the CNS more vulnerable to the inflammatory signals produced in peripheral tissues. Such increases in BBB permeability are associated with cognitive decrements ([@B119]--[@B121]). Interestingly, a few reports suggest that this HFD-induced BBB defect may lead not only to cognitive impairment but could also be the connection between Western diet consumption and Alzheimer's disease ([@B122], [@B123]).

HFD and Sex Hormones {#S3-2}
--------------------

The effects of dietary lipids upon sex hormones have been the focus of many studies since the early 1990s, particularly with regard to female sex hormones. Such interest in female hormones was triggered by data showing blood and urine estrogen levels to correlate positively with breast cancer risk in postmenopausal women ([@B124]). Coupled to the role of estrogens in the regulation of Alzheimer's disease, manipulating estrogen levels has been extensively investigated, including how this can be achieved *via* dietary manipulations.

There is now a general consensus that a low-fat diet significantly reduces estrogen levels in healthy postmenopausal women ([@B125], [@B126]). Dietary effects on serum estradiol levels were assessed in a study comparing estradiol levels from Caucasian and Asian women ([@B127]). Postmenopausal Asian women consumed a total of 19% of their calories from lipids, whereas in Caucasian women, this percentage was 38%. Serum estradiol levels were significantly lower in Asian women, being 30--70% lower than postmenopausal Caucasian women. Dietary intervention studies in women to assess dietary lipid impact on estradiol levels usually apply a low-lipid diet, with only 10--25% of calories being lipid derived. Results from such studies show significant changes occurring as early as 3 months after the intervention, with the general serum estradiol reduction being around 13% ([@B126], [@B128]--[@B130]).

The consumption of omega-3 fatty acids is another possible dietary intervention that can modulate estradiol levels. Dietary omega-3 and omega-6 PUFA are both required in order to optimize health but can have differential effects on the inflammatory response. Omega-6 PUFA consumption increases the levels of a number of proinflammatory mediators, including prostaglandin E2 (PGE2) and leukotriene B4 (LB4), while omega-3 raises the levels of mediators with relatively lower inflammatory activity, such as prostaglandin E3 (PGE3) and leukotriene B5 (LB5). Both PGE2 and PGE3 and LB4 and LB5 are produced by the same enzymes, cyclooxygenase and 5-lipoxygenase, respectively. By enhancing substrate competition, omega-3 supplementation can reduce PGE2 and LB4 production, thereby attenuating the inflammatory response ([@B131], [@B132]). Furthermore, PGE2 can induce aromatase expression, thereby increasing the conversion of androgens to estrogens ([@B133]). This is an important mechanism that allows omega-3 PUFA consumption to inhibit estrogen production. Just as a low-lipid diet can decrease estradiol levels, a HFD can have the opposite effect. Young et al. ([@B134]) have shown a 36.6% increase in the plasma estradiol levels of postmenopausal women after 8 weeks of HFD, compared to that at baseline. However, this study was not able to show the influence of a low-fat, high omega-3 PUFA diet on estradiol levels.

While estradiol can have detrimental effects on peripheral tissues in postmenopausal women, including increasing breast cancer risk, studies in the CNS have shown some opposite effects. The protective role that sex hormones perform in the brain is well established, including from the use of several different experimental models, ranging from stroke to neurodegenerative disorders ([@B135]). Although the neuroprotective role of estrogen hormones is widely acknowledged, arising in part from data showing estrogens to increase anti-inflammatory mediators and protect against excitotoxicity, its use as a therapeutic agent is limited due to its activity in peripheral tissues, where it can lead to feminization and altered gonadal function as well as correlating positively with increased cancer risk, predominantly breast and endometrial cancers. Consequently, research has focused on the utility of using selective ER modulators. Tissue- and cell-specific ER modulators are a promising alternative, should they combine the desired pharmacological effect with little to no side effects.

Although not within the scope of this review, a HFD has opposite effects with regard to male sex hormone levels. Mice submitted to a HFD regimen of a duration of 10 weeks showed higher serum estradiol levels, as expected, but lower concentrations of both luteinizing, and consequently, testosterone hormones ([@B136]). Interestingly enough, metformin treatment of obese mice induced by HFD is capable of partially reverse obesity-induced elevated estradiol serum levels and decreased serum testosterone, while rescuing several fertility parameters ([@B137]).

DER and Glucocorticoids {#S3-3}
-----------------------

Dietary energy restriction can be psychologically stressful. Being characterized by food deprivation and starvation, it can be coupled to negative emotions, such as anxiety, depression, and irritability ([@B138]). As a stressful stimulus, DER can increase HPA axis activity in a variety of species, thereby increasing an important stress indicator, namely, circulating glucocorticoid hormone levels. Furthermore, the glucocorticoid increase during DER would be expected to modulate metabolic functions, including by enabling nutrient mobilization that may be further catabolized for energy, such as the stimulation of gluconeogenesis, protein catabolism, which increases the release of constituent amino acids, and lipolysis, which sensitizes adipose tissue stored as triglyceride to the action of lipolytic substances (growth hormone and catecholamines), resulting in glycerol and fatty acids ([@B139]).

The theory of hormesis, whereby mild stressors can be beneficial, may help to explain the DER mechanisms ([@B140]). Unlike other chronic stressful stimuli, DER can have many favorable effects for the organism, including counteracting inflammation, extending life span, and reducing the prevalence of age-related diseases. It is theorized that the DER potentiation of glucocorticoids release may contribute to increased stress resistance, protecting the organism not only against the stressor itself but also by upregulating adaptive pathways that protect the organism against the exacerbation of inflammation, infection, and metabolic disorders that can disturb homeostasis ([@B141]--[@B144]). Noteworthy, Dhurandhar et al. ([@B145]) recently proposed that the DER protective mechanisms may involve stress-related interceptive cues, as hunger in the absence of dietary restriction, as induced by a ghrelin agonist, promotes the same beneficial effects as DER, counteracting inflammation, aging, and neurodegeneration.

Among the mechanisms by which DER effects occur, neuroendocrinological alterations may play an important role ([@B146]). As previously noted, increased glucocorticoid concentrations following DER occur in various species. For instance, glucocorticoids are moderately increased by DER in rodents, where it is suggested to play a role in the DER effect ([@B146]--[@B150]). Free corticosterone levels are increased in rats after DER at any point in lifespan, when compared to age-matched *ad libitum* ([@B151]). This has led to the proposal that a lifetime DER-induced daily hyperadrenocorticism may retard aging ([@B152]). Levay et al. ([@B24]) tested different DER doses of calorie restriction (CR) in rats ranging from 12.5 to 50% and showed that all the doses caused an increase in corticosterone levels following a dose--response trend, with increasing restriction associated with higher glucocorticoid levels ([@B24]). Interestingly, a study that evaluated whether DER would similarly affect cortisol concentrations in wild mice not subjected to many generations of laboratory selection similarly showed that DER elevates corticosterone levels throughout life, suggesting that this DER effect is not altered by genetic breeding effects ([@B153]).

In humans, DER has been shown to increase perceived stress and circulating cortisol concentrations ([@B154]). Moreover, athletes have higher cortisol secretion following DER ([@B155]), as do individuals with anorexia nervosa ([@B156]). The study of eight participants who were subjected to DER for 2 years in a closed ecological space (Biosphere 2) also showed increased morning total cortisol ([@B157]). Interestingly, Grayson et al. ([@B158]) reported that rodent weight loss induced by DER increased basal HPA axis activity, unlike the same level of weight loss induced by bariatric surgery. Cortisol is usually released in a circadian rhythm, being an important aspect of the circadian system. Higher circulating cortisol levels are observed during the early morning, with lower levels evident around midnight. Remarkably, the elevated glucocorticoid levels after DER, which is accompanied by an oscillation in the levels of GRs, follow an altered circadian profile ([@B147], [@B159]). Another study, using 40% CR mice, in comparison to *ad libitum* fed controls, showed a 10-fold increase of plasma corticosteroid levels at 7:00 a.m., a 2-fold increase at 4:00 p.m., and no difference at 11:00 p.m. in the circadian cycle ([@B160]).

During Ramadan, adult Muslims refrain from eating during daytime. Ramadan can be considered a DER, in which the frequency of food consumption is restricted \[intermittent fasting (IF)\] but not the levels of calories consumed. Literature data suggest that Ramadan decreases the amplitude of the cortisol circadian rhythm by increasing its nocturnal levels while decreasing its diurnal circulating levels ([@B161]--[@B163]). A serum cortisol increase at 3:00 p.m. can occur in Ramadan ([@B164]). During Ramadan, although still within the normal reference ranges, immune cells can also significantly decrease, as well as proinflammatory cytokines and chemokines levels, with consequences, e.g., cancer-associated processes ([@B165], [@B166]).

However, although it has commonly been shown that DER increases cortisol levels in primates and rodents, there is also evidence to suggest otherwise. It seems that cortisol modulation by DER varies depending on the species, protocol, and other circumstances studied. For instance, it has recently been shown that a mild 25% CR diet does not alter the salivary cortisol levels of overweight men and women ([@B167]). In another study with obese individuals submitted to mild CR for 3 weeks, although reduced cortisol production and the metabolism of cortisol and cortisone were observed, there was no alteration on plasma cortisol levels. Conversely, in the same study, obese individuals starved for 6 days showed increased plasma cortisol levels ([@B168]). Also, Sticker et al. ([@B169]) showed that 50% CR in horses led to decreased plasma cortisol levels, compared to controls. Accordingly, Glade et al. ([@B170]) showed that during prolonged DER, young horses on an 80% CR also showed decreased cortisol levels, when compared with horses fed with meals containing 160% of their energy requirements.

Importantly, not in all glucocorticoid-sensitive cell types may derive stress inoculation benefits from DER-induced cortisol release. For instance, previous studies suggest that glucocorticoids can render hippocampal and cortical neurons more vulnerable to metabolic, excitotoxic, and oxidative damage ([@B171]). Although it was previously demonstrated that DER upregulates brain heat shock proteins ([@B172], [@B173]), GR activation can downregulate the expression of several genes, including heat shock protein 70, known to be important to counteract stress-induced cell damage ([@B174]). DER in rodents leads to glucocorticoid release that can reduce neuronal sensitivity to glucocorticoids by promoting a feedback suppression on the levels of the potentially damaging GR, thereby increasing the resistance to injury ([@B175]).

A large body of evidence strengthens the proposed link between glucocorticoids and the anti-inflammatory effects of DER in rodents. Besides its metabolic actions, glucocorticoids are also known for their anti-inflammatory activities due to the inhibition of key inflammatory transcriptional regulators, such as the activator protein-1 (AP-1) and NF-κB, known to activate the transcription of proinflammatory cytokines ([@B39]).

Dietary energy restriction has also been linked to protection against inflammation. Vasconcelos et al. ([@B176]) showed that the IF protocol prevents or mitigates cognitive deficits, inflammatory genes transcription, and the diverse array of systemic LPS-induced cytokines in the brain and the periphery. Furthermore, 50% CR also reduces sickness behavior, fever, and peripheral immune markers following LPS injection, which was also modulated by DER duration ([@B177], [@B178]). In this DER protocol, elevated circulating corticosterone levels were evident, which the authors suggest contributes to the diminished proinflammatory signals in these animals ([@B178]). In another study, 40% CR in mice also prevented the LPS-induced proinflammatory cytokines upregulation, which was again accompanied by increased glucocorticoid production ([@B179]). Supporting this theory, previous data reported that adrenalectomized mice are much more sensitive to the lethal effect of LPS, which is prevented by the pretreatment with dexamethasone ([@B33], [@B49]). Such data highlight the immune-regulatory effects of glucocorticoids, including in CR paradigms.

Inflammation has long been associated with the development of cancer, which partly explains the association of obesity and tumorigenesis. By contrast, DER powerfully inhibits the development of cancer in many studies ([@B180]), including in wild mice as well as laboratory-reared rodents, indicating that laboratory selection does not interfere in this effect ([@B153]). Both topical and oral glucocorticoid treatments decrease tumor development in rodents ([@B181]--[@B185]). Adrenalectomy reverses the inhibition of tumorigenesis by DER in mice and glucocorticoids supplementation restores it, suggesting that adrenal hormones play an important role in mediating this DER effect ([@B186]--[@B188]).

An extensive literature shows inflammation to be a risk factor for cognitive impairment and dementia, with neuroinflammatory processes contributing to neurodegeneration ([@B189], [@B190]). Most neurodegenerative conditions are associated with chronic inflammation, which is widely accepted as contributing to the pathophysiology of neurodegenerative conditions ([@B191]--[@B193]). DER can prevent or attenuate inflammation associated with neurodegeneration ([@B194]--[@B196]). Studies also suggest that glucocorticoids play an important role, with some differential effects that are dependent on whether they are applied acutely or chronically, in neurodegeneration, such as in Alzheimer's disease, being associated with chronic glucocorticoids ([@B197]--[@B199]), while acute conditions, such as ischemic stroke, benefiting from the acute effects of glucocorticoids ([@B171]). Such effects are relevant both clinically and in animal models.

Despite the DER-induced increase in glucocorticoids classically known for their anti-inflammatory action, studies have shown mixed results when evaluating the immune response to infection and pathogen clearance efficiency in animals submitted to DER protocols. In primates and rodent studies, while DER can improve clearance and survival after bacterial infection and enhance interferon gamma (IFN-γ) production, it can promote a deficient innate immune response with reduced ability to control infections by monocytes and macrophages ([@B200]--[@B204]). Patel and Finch ([@B205]) suggest that DER-induced glucocorticoid release may promote a differential effect on immunity in different parts of the organism, for instance, activating pathways close to the infectious focus that are not suppressed by glucocorticoids and attenuating inflammation at other locations.

A brief summary of DER and HFD modulatory effects on neuroinflammation through glucocorticoid signaling is outlined in Figure [2](#F2){ref-type="fig"}.

![**Glucocorticoid-mediated effects of dietary interventions**. Both HFD and DER results in increased blood concentrations of glucocorticoids. However, opposing effects are observed. HFD, *via* glucocorticoids release, cause detrimental effects to the brain and organism, while DER-induced glucocorticoids release leads to protective effects.](fendo-07-00009-g002){#F2}

DER and Sex Hormones {#S3-4}
--------------------

Numerous studies have demonstrated that DER protocols affect sex hormone levels. In rhesus monkeys, for instance, 30% CR deferred the age-related dehydroepiandrosterone decline in males ([@B28]). Accordingly, Levay et al. ([@B24]) observed a dose--response decrease in testosterone levels in male rats with increasing CR severity. This effect was also observed for the IF protocol ([@B32]). A severe CR protocol in men also decreased levels of testosterone and estradiol while increasing levels of SHBG ([@B31]). In women, IF also increases SHBG levels, although CR more significantly reduces dehydroepiandrosterone levels ([@B206]). In the Biosphere 2 study, Walford et al. ([@B157]) observed an increase in levels of androstenedione and SHBG in humans (both in male and female participants), while the levels of estradiol, but not testosterone, decreased in men.

In contrast to these results, Martin et al. ([@B29]) observed that male rats submitted to IF or females under 40% CR had increased levels of testosterone. In a subsequent study, they observed that either a 40% CR or an IF protocol increased the testosterone/estrogen ratio, consistent with a hyper-masculinization state. A similar effect was also observed in females under the 40% CR protocol ([@B30]). Furthermore, Kumar and Kaur ([@B32]) showed that IF induced a significant decrease in luteinizing hormone, associated with diminished levels of estradiol in female rats, which completely suppressed the estrous cycle. Other studies also showed DER to inhibit estradiol levels ([@B29], [@B30]).

In conclusion, the effects of both DER interventions on sex hormones levels -- including the testosterone/estrogen ratio -- as well as the relevance of this modulation on DER anti-inflammatory properties are still obscure and have yet to be clarified. The interrelationship between sex hormones and neuroinflammation, as discussed above, is summarized in Figure [3](#F3){ref-type="fig"}.

![**Effects of sex hormones on the inflammatory process**. Presence of systemic inflammatory markers correlates inversely with blood concentrations of sex hormones, while hormonal reposition reduces both central and peripheral cytokine production. In the CNS, testosterone has protective roles both in neurons and glial cells, where it shows an anti-inflammatory action. Estradiol also has anti-inflammatory properties in glial cells (astrocytes and microglia). On the other hand, estradiol levels in postmenopausal women positively correlate with breast cancer incidence. A HFD raises estradiol blood levels in postmenopausal women, increasing breast cancer risk. The effects of different DER protocols on sex hormone levels are more controversial. In black, effects of and on both testosterone and estradiol; in light gray, effects related to estradiol; in dark gray, effects related to testosterone.](fendo-07-00009-g003){#F3}

Concluding Remarks {#S4}
==================

In conclusion, glucocorticoids have been historically characterized as mediators of many anti-inflammatory effects observed within DER protocols, closely implicating glucocorticoid pathways in DER, including in the development of future pharmacological interventions that could mimic DER benefits. In contrast, extensive data support the hypothesis that the detrimental effects of a HFD upon cognitive function and behavior are caused by enhanced glucocorticoid signaling accompanied by neuroinflammation. As such, it is clear that there is more to glucocorticoid effects than simply its serum levels. Although both DER and HFD contribute to enhanced glucocorticoid blood concentration, its effects are quite opposite regarding health and, specifically, inflammation. Also, DER may induce its positive effects through other different mechanisms not related to glucocorticoid signaling, as may be the case for the detrimental effects of a HFD.

Given that androgen and estrogen levels also appear to be variably modulated by DER interventions and overall dietary lipid load, which is at least partly dependent on sex, age, and inflammatory status, it is possible that these hormones could have a relevant role to play in DER anti-inflammatory mechanisms and HFD-induced inflammation. However, this effect is still unclear. It is therefore important that future research should better clarify the role that such sex hormones play in DER and HFD mechanisms.
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